Atacand® Approved for the Treatment of Chronic Heart Failure, Europe

   blogdigger

AstraZeneca today announced that the European Mutual Recognition Variation Procedure (MRP) evaluating the use of Atacand® (candesartan cilexetil), a selective angiotensin receptor blocker (ARB) in the treatment of chronic heart failure (CHF) has been completed... click link for more info.

- link to Atacand® Approved for the Treatment of Chronic Heart Failure, Europe -
Last update: 01/25/2005

Recommended Reading

The Local Government Elections (Changes to the Franchise and Qualification of Members) Regulations 1995: Representation of the People (Statutory Instruments: 1995: 1948)	Speech of John Stuart Mill, M.P., on the admission of women to the electoral franchise: Spoken in the House of Commons, May 20th, 1867	How to Franchise Your Business: A Quick Step-By-Step Guide	Competition Policy and Vertical Restraints: Franchising Agreements
Retailing (Self-starters S.)	Tax considerations in technology licensing agreements and franchise agreements	The New York State corporate franchise tax	Franchise Affair